{
    "nct_id": "NCT06778863",
    "official_title": "GUARDIAN-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation",
    "inclusion_criteria": "* Patients must be at least 18 years of age at the time of signing the informed consent.\n* Patients must be willing and able to provide written informed consent\n* Patients must have locally advanced or metastatic solid tumors that have progressed after standard of care therapy or for which no standard therapy exists\n* Tumors must harbor a TP53 R175H variant mutation confirmed by an accredited laboratory-based test\n* Patients must be HLA-A*02:01 positive by central assay\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at the time of enrollment\n* Adequate hematological, renal and hepatic function\n* Per Investigator judgement, patient is willing and able to complete study visits and/or procedures per the protocol and comply with study requirements for study participation\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with Li-Fraumeni syndrome or other known germline p53 R175H mutation\n* Patients who have received other p53 R175H-directed therapies\n* Patients who have not fully recovered from adverse events due to previous anticancer therapies\n* Patients with active infection requiring systemic antimicrobial therapy\n* Any other primary malignancy within the 2 years prior to enrollment (except for non- melanoma skin cancer, carcinoma in situ (eg, cervix, bladder, breast) or prostate cancer in remission.\n* Known active central nervous system metastases and/or carcinomatous meningitis",
    "miscellaneous_criteria": "Key"
}